The 3,349 patients-based prospective ADAPT-DES IVUS sub-study, which is a part of the Cardiovascular Research Foundation’s Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study, included the company’s Eagle Eye Gold IVUS catheters.

The study analysis included assessment of lesion morphology by using both traditional grayscale IVUS and Volcano’s proprietary VH IVUS tissue characterization technology.

The results demonstrated a 50% reduction in the incidence of stent thrombosis (a blood clot on the surface of a stent) and 33% reduction in MI, that began as soon as 30 days post procedure, and continued for 12 months.

Columbia University College of Physicians and Surgeons medicine professor Gregg Stone said previously, the additive value of IVUS as an independent predictor of stent thrombosis, MI and death had not been assessed in the 8,583 patient-based prospective, multi-center registry ADAPT-DES study.

"The ADAPT-DES IVUS sub-study provides the strongest evidence to date that use of IVUS to guide optimizing placement improves patient outcomes," Stone added.

Volcano president and chief executive officer Scott Huennekens said the results at 30 days and 12 months meaningfully advance the field of interventional cardiology, and also have important implications for the healthcare delivery system as institutions seek strategies to improve the quality of care and avoid penalties imposed by the new CMS 30-day readmission policy.

"With the insight our technologies such as IVUS provide, Volcano can help physicians and healthcare institutions answer the growing demand for truly personalized medicine that is appropriate, evidence-based and accountable," Huennekens added.